This is a receptor tyrosine kinase inhibitor that targets VEGFR1, VEGFR2/KDR, VEGFR3, c-Kit, PDGFR-alpha, and the fibroblast growth factor receptors FGFR1-3.44 Chai reported on ongoing 8-month CR to radiotherapy and anlotinib for an orbital NMC.45 Jiang treated a patient with pulmonary NMC with radiotherapy plus anlotinib with a short-lived partial response.46 We are unaware of reports of this drug being used in the absence of concomitant radiation. Here, KDR is linked to nut midline carcinoma.